

November 19, 2015

U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549

Attention: Suzanne Hayes
Scot Foley

**Re: OncoGenex Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed October 29, 2015
File No. 033-207670**

Ladies and Gentlemen:

On behalf of OncoGenex Pharmaceuticals, Inc. (the "**Company**"), we are submitting this letter and the following information in response to a letter, dated November 5, 2015, from the staff (the "**Staff**") of the Securities and Exchange Commission (the "**Commission**") with respect to the Company's Registration Statement on Form S-3 filed with the Commission on October 29, 2015.

We have incorporated the Staff's comment into this response letter in bold italics and our response is set forth below.

General

- 1. We note that you have submitted an application for confidential treatment relating to an exhibit you filed with your quarterly report on Form 10-Q for the quarterly period ended June 30, 2015. Please be advised that we will not be in a position to grant effectiveness to your registration statement until such time as this application has completed processing or is withdrawn.***

The Company acknowledges the Staff's comment and respectfully advises the Staff that the confidential treatment order (File No. 033-80623- CF#32888) relating to Exhibit 10.2 to the Company's quarterly report on Form 10-Q for the quarter ended June 30, 2015 was issued on November 19, 2015.

* * *

Should the Staff have additional questions or comments regarding the foregoing, please do not hesitate to contact the undersigned at (206) 389-4559 or, in his absence, Amanda Rose at (206) 389-4553.

Sincerely,

FENWICK & WEST LLP

/s/ James D. Evans

James D. Evans

cc: John Bencich, OncoGenex Pharmaceuticals, Inc.
Alan Smith, Esq., Fenwick & West LLP
Amanda Rose, Esq., Fenwick & West LLP